Peak Pharmaceutical Partners with Shanghai Pharma Subsidiary to Optimize Neffy Supply Chain and Channel Development in China
Peak Pharmaceutical Co., Ltd. announced a strategic partnership with SPH Kyuan Trade, a core subsidiary...
Company
Changchun High & New Technology Secures NMPA Clinical Filing Acceptance for GenSci144 SLC6A19 Inhibitor in Chronic Kidney Disease
Changchun High & New Technology Industries (Group) Inc. (SHE: 000661) announced that the National Medical...
China Medical System Secures NMPA Approval for CMS-D001 TYK2 Inhibitor in Ulcerative Colitis and Crohn’s Disease
China Medical System Holdings Limited (CMS, HKG: 0867) announced it has received clinical trial authorization...
MicroPort NeuroTech Secures FDA Approval for NUMEN Helia Spring Coil System – Advanced Solution for Complex Neurovascular Lesions
MicroPort NeuroTech Limited (HKG: 2172) announced it has received marketing approval from the U.S. Food...
Eli Lilly Reports Positive Phase 1b Results for VERVE-102 Base Editing Therapy with Sustained LDL-C Reductions Up to 18 Months
Eli Lilly and Company (NYSE: LLY) announced positive interim results from the Phase 1b Heart-2...
Insilico Medicine and Eterna Therapeutics Expand AI-Driven Partnership into Skin Anti-Aging and Scientific Skincare
Insilico Medicine (HKG: 3696), a generative artificial intelligence (AI)-driven biotechnology company, announced an expanded strategic...
ZBD Pharmaceutical Secures Marketing Rights for Teruisi’s CD20-Targeted ADC TRS005 in Relapsed/Refractory Non-Hodgkin Lymphoma
Heilongjiang ZBD Pharmaceutical Co., Ltd. (SHA: 603567) announced a strategic agent marketing agreement with fellow...
Pierre Fabre Secures EU Recommendation for Braftovi Combo in First-Line BRAF V600E-Mutant Metastatic Colorectal Cancer
Pierre Fabre Laboratories announced that the European Medicines Agency’s Committee for Medicinal Products for Human...
OTR Therapeutics Secures NMPA Approval for Phase Ib/II Trial of OTR-8100 – Best-in-Class Small Molecule Inhibitor for Malignant Tumors
OTR Therapeutics announced that China’s National Medical Products Administration (NMPA) has granted approval to initiate...
D3 Bio Secures Breakthrough Therapy Designation for Elisrasib – Next-Generation KRAS G12C Inhibitor for First-Line NSCLC
D3 Bio announced that China’s Center for Drug Evaluation (CDE) of the National Medical Products...
Sinocelltech Files for Hong Kong Secondary Listing to Expand Global Capital Access and Therapeutic Portfolio
Sinocelltech Group Ltd (SHA: 688520) has filed its prospectus with the Hong Kong Stock Exchange,...
Lifetech Scientific to Acquire Starway Medical Technology in $276 Million Deal to Expand Structural Heart Portfolio
Lifetech Scientific Corporation (HKG: 1302) announced plans to acquire a 96.46% stake in fellow Chinese...
Biocytogen Launches RenSuper Workstation, AI-Driven Antibody Discovery Platform to Transform Therapeutic Development
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (SHA: 688796, HKG: 2315) announced the official launch of RenSuper...
Johnson & Johnson MedTech Partners with Beijing Shijitan Hospital to Establish China’s First Split-Type Surgical Robot Training Base
Johnson & Johnson MedTech announced a strategic partnership with Beijing Shijitan Hospital, a Class 3A...
Cloudbreak Pharma Submits FDA IND for CBT-358, Novel SFA+ Technology-Based Dry Eye Treatment
Cloudbreak Pharma Inc. (HKG: 2592) announced it has submitted an Investigational New Drug (IND) application...
Henlius Biotech’s PD-1 Inhibitor Hetronifly Receives CHMP Recommendation for Squamous NSCLC in EU
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that the European Medicines Agency’s Committee for Medicinal...
Boehringer Ingelheim’s Ofev Receives CHMP Endorsement for Idiopathic and Progressive Pulmonary Fibrosis
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a...
Regeneron’s Otarmeni Gene Therapy Accepted for EMA Accelerated Review as First Potential Treatment for OTOF-Related Hearing Loss
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the European Medicines Agency (EMA) has accepted for...
Everest Medicines Secures South Korean Approval for Velsipity in Ulcerative Colitis Following Pfizer-Arena Legacy
Everest Medicines (HKG: 1952) announced it has received marketing approval in South Korea for Velsipity...
Jiangsu Chia Tai Tianqing Secures NMPA Priority Review for LM-302 ADC in CLDN18.2-Positive Gastric Cancer
Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd (HKG:...